<DOC>
	<DOCNO>NCT00703014</DOCNO>
	<brief_summary>The objective trial evaluate whether Corifollitropin Alfa treatment induction multifollicular growth woman undergo controlled ovarian stimulation ( COS ) prior vitro fertilization ( IVF ) intracytoplasmic sperm injection ( ICSI ) safe pregnant participant offspring . The primary endpoint take-home baby rate calculate number participant ongoing pregnancy Base Trial P05787 ( NCT00696800 ) least one live bear infant relative number participant Base Trial , number participant Base Trial Embryo Transfer ( ET ) .</brief_summary>
	<brief_title>Pregnancy Neonatal Follow-up Ongoing Pregnancies Established Clinical Trial P05787 ( P05712 )</brief_title>
	<detailed_description>This follow-up protocol prospectively monitor pregnancy , delivery , neonatal outcome woman treat Corifollitropin Alfa recFSH become pregnant Base Trial P05787 ( NCT00696800 ) . For trial , study specific assessment require , information obtain standard practice use .</detailed_description>
	<mesh_term>Ganirelix</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Participants receive least one dose either Corifollitropin Alfa Puregon®/Follistim® AQ Cartridge Base Trial P05787 ( NCT00696800 ) ; Ongoing pregnancy confirm ultrasound least 10 week embryo transfer Base Trial P05787 ( NCT00696800 ) ; Able willing give write informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neonatal outcome</keyword>
	<keyword>Congenital malformation</keyword>
	<keyword>In-Vitro fertilization</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Follow-up</keyword>
</DOC>